Glubio Completes Series A+ Financing Of $22 Million To Advance The Development Of Novel Tpd Drugs
Round Type
Series A
Description
GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021.
Quick answer
GluBio Therapeutics raised an undisclosed amount in a Series A round, dated August 1, 2022.
- How much did GluBio Therapeutics raise?
- GluBio Therapeutics raised an undisclosed amount in a Series A round on August 1, 2022.
- What does GluBio Therapeutics do?
- GluBio Therapeutics is a pioneering TPD company dedicated to developing targeted protein degraders for human diseases with unmet medical needs.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as GluBio Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Novome raised an undisclosed amount (Funding Round) on September 15, 2022.
- Carver raised an undisclosed amount (Seed) on September 15, 2022.
- Adaptive Biotechnologies Corporation raised an undisclosed amount (Grant) on September 12, 2022.
- Photys Therapeutics raised $75M (Series A) on September 8, 2022.
- Autobahn Therapeutics raised an undisclosed amount (Funding Round) on September 8, 2022.
- Inherent Biosciences raised an undisclosed amount (Series A) on September 7, 2022.
Who to call at GluBio Therapeutics, and when
A new round usually means GluBio Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GluBio Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GluBio Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GluBio Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GluBio Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansGluBio Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.